(Total Views: 777)
Posted On: 10/29/2021 11:37:17 PM
Post# of 72445
Many signs converging:
1. FDA fast track designation- January
2. Validation by 2 independent machine learning studies- March
https://www.ipharminc.com/press-release/2021/...sars-cov-2
3. Peer-Reviewed scientific article published in journal Viruses- March-- https://www.mdpi.com/1999-4915/13/2/271
4. 2 separate Data Monitoring Committee safety reviews are completed on PH II patients- April and after.
5. Subsequent FDA approved Compassionate use begins in hospitalized patients using Brilacidin.
6. PH II results anticipated week of Nov. 8th
7. Management 8ks new milestone-based incentive package for CEO and Board on Oct. 14
8. Dr. Degrado, IPIX scientific advisor and developer of Brilacidin publishes new paper and gives prestigious lecture on de novo design of membrane-interactive peptides . Oct. 21st
9. IPIX share price rises last few sessions
Did I miss anything?
1. FDA fast track designation- January
2. Validation by 2 independent machine learning studies- March
https://www.ipharminc.com/press-release/2021/...sars-cov-2
3. Peer-Reviewed scientific article published in journal Viruses- March-- https://www.mdpi.com/1999-4915/13/2/271
4. 2 separate Data Monitoring Committee safety reviews are completed on PH II patients- April and after.
5. Subsequent FDA approved Compassionate use begins in hospitalized patients using Brilacidin.
6. PH II results anticipated week of Nov. 8th
7. Management 8ks new milestone-based incentive package for CEO and Board on Oct. 14
8. Dr. Degrado, IPIX scientific advisor and developer of Brilacidin publishes new paper and gives prestigious lecture on de novo design of membrane-interactive peptides . Oct. 21st
9. IPIX share price rises last few sessions
Did I miss anything?
(8)
(1)
